Aijia Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aijia Zhang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Guanghui Huang
Macau University of Science and Technology
3 shared publicationsFangtian Ying
Faculty of Humanities and Arts, Macau University of Science and Technology, Taipa, Macau (SAR), China
2 shared publications- Guanghui Huang
Faculty of Humanities and Arts, Macau University of Science and Technology, Macau, China
2 shared publications - Jue Wang
Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology, Macau, China
2 shared publications Runqing Lin
Faculty of Humanities and Arts Macau University of Science and Technology Taipa Macau
2 shared publicationsXuexing Luo
Faculty of Humanities and Arts, Macau University of Science and Technology,Taipa, Macau,China
2 shared publications
Latest Publications
- 21 April 2026
- Published by SAGE Publications in Journal of Health Psychology
Museum-based creative arts interventions for people living with dementia: A scoping review
While global ageing has heightened dementia prevalence, current treatments remain limited in efficacy and are burdened by side effects. Against this background, art therapy has gained attention as an innovative alternative intervention for dementia. For non-pharmacological dementia care, museums are inclusive cultural spaces offering safe and supportive environments. This review examines how Museum-Based Creative Arts Interventions (MCAIs) can alleviate dementia symptoms and evaluates their benefits. We searched six databases for studies meeting three criteria, that is, museum/gallery-based interventions, dementia-diagnosed participants, and creative arts interventions as the primary treatment. Among 1080 screened articles, 31 qualified studies were selected for inclusion. Overall, MCAIs help alleviate cognitive and emotional symptoms while enhancing the quality of life for people living with dementia by strengthening social connections, self-esteem, communication, and shared meaning. This review highlights the beneficial role of museums with art interventions in health. Findings can inform museum-health collaborations and cultural institutions’ public wellness strategies.
- 21 April 2026
- Published by SAGE Publications in Journal of Health Psychology
Museum-based creative arts interventions for people living with dementia: A scoping review
While global ageing has heightened dementia prevalence, current treatments remain limited in efficacy and are burdened by side effects. Against this background, art therapy has gained attention as an innovative alternative intervention for dementia. For non-pharmacological dementia care, museums are inclusive cultural spaces offering safe and supportive environments. This review examines how Museum-Based Creative Arts Interventions (MCAIs) can alleviate dementia symptoms and evaluates their benefits. We searched six databases for studies meeting three criteria, that is, museum/gallery-based interventions, dementia-diagnosed participants, and creative arts interventions as the primary treatment. Among 1080 screened articles, 31 qualified studies were selected for inclusion. Overall, MCAIs help alleviate cognitive and emotional symptoms while enhancing the quality of life for people living with dementia by strengthening social connections, self-esteem, communication, and shared meaning. This review highlights the beneficial role of museums with art interventions in health. Findings can inform museum-health collaborations and cultural institutions’ public wellness strategies.
- Top Cited Papers
- 17 July 2024
- Published by Wiley in International Journal of Mental Health Nursing
- Vol. 33 (6) , 1743-1760
Emergence of Artificial Intelligence Art Therapies (AIATs) in Mental Health Care: A Systematic Review
The application of artificial intelligence art therapies (AIATs) in mental health care represents an innovative merger between digital technology and the therapeutic potential of creative arts. This systematic review aimed to assess the effectiveness and ethical considerations of AIATs, incorporating robots, AI painting and AI Chatbots to augment traditional art therapies. Aligning with the Preferred Reporting Items for systematic reviews (PRISMA) guidelines, we meticulously searched PubMed, Cochrane Library, Web of Science and CNKI, resulting in 15 selected articles for detailed analysis. To ensure methodological quality, we applied the Joanna Briggs Institute (JBI) criteria for quality assessment and extracted data using the PICO(S) format, specifically targeting randomised controlled trials (RCTs). Our findings suggest that AIATs can profoundly enhance the therapeutic experience by providing new creative outlets and reinforcing existing methods, despite possible drawbacks and ethical challenges. This examination underscores AIATs' potential to enrich mental health therapies, emphasising the critical importance of ethical considerations and the responsible application of AI as the field evolves. With a focus on expanding treatment efficacy and patient expressiveness, the promise of AIATs in mental health care necessitates a careful balance between innovation and ethical responsibility.Trial Registration: PROSPERO: CRD42024504472
- 17 July 2024
- Published by Wiley in International Journal of Mental Health Nursing
- Vol. 33 (6) , 1743-1760
Top Cited PapersEmergence of Artificial Intelligence Art Therapies (AIATs) in Mental Health Care: A Systematic Review
The application of artificial intelligence art therapies (AIATs) in mental health care represents an innovative merger between digital technology and the therapeutic potential of creative arts. This systematic review aimed to assess the effectiveness and ethical considerations of AIATs, incorporating robots, AI painting and AI Chatbots to augment traditional art therapies. Aligning with the Preferred Reporting Items for systematic reviews (PRISMA) guidelines, we meticulously searched PubMed, Cochrane Library, Web of Science and CNKI, resulting in 15 selected articles for detailed analysis. To ensure methodological quality, we applied the Joanna Briggs Institute (JBI) criteria for quality assessment and extracted data using the PICO(S) format, specifically targeting randomised controlled trials (RCTs). Our findings suggest that AIATs can profoundly enhance the therapeutic experience by providing new creative outlets and reinforcing existing methods, despite possible drawbacks and ethical challenges. This examination underscores AIATs' potential to enrich mental health therapies, emphasising the critical importance of ethical considerations and the responsible application of AI as the field evolves. With a focus on expanding treatment efficacy and patient expressiveness, the promise of AIATs in mental health care necessitates a careful balance between innovation and ethical responsibility.Trial Registration: PROSPERO: CRD42024504472
- Open Access
Group arts therapies for patients with schizophrenia: a protocol of systematic review and meta-analysis
Introduction: Schizophrenia, a chronic mental problem, significantly impacts cognition, emotion and social functioning. Conventional pharmacotherapy faces challenges including numerous side effects, low adherence to medication and substantial costs. In this context, group arts therapies (GATs) emerge as a promising complementary approach for symptom alleviation in schizophrenia patients. Nonetheless, the effectiveness and safety of GATs are yet to be firmly established. This study aims to systematically assess the therapeutic impact of all group-based artistic interventions as complementary treatments for schizophrenia, focusing on their potential benefits. Methods and analysis: This study will search four English-language databases (PubMed, Web of Science, Cochrane Library and Embase), two Chinese databases (Wanfang Data and China National Knowledge Infrastructure) and three Korean databases (RISS, Korean Citation Index and DBpia) from their inception until October 2023. It will include all randomised controlled trials that compare GATs for schizophrenia with standard rehabilitation methods. The primary outcome is the improvement in patients’ positive and negative symptoms. Methodologies such as bias risk assessment, data synthesis, sensitivity analysis and subgroup analysis will be implemented using Review Manager V.5.4. Study results with high heterogeneity will be merged using a random-effects model ( I 2 >50% or p<0.1). In cases where meta-analysis is not viable due to significant clinical and methodological heterogeneity, a qualitative summary of the findings will be provided. Ethics and dissemination: The data used in this systematic review are anonymised, devoid of any private information, eliminating the requirement for ethical approval. Dissemination of the research findings will be conducted via peer-reviewed publications. PROSPERO registration number: CRD42023471583.
Open AccessGroup arts therapies for patients with schizophrenia: a protocol of systematic review and meta-analysis
Introduction: Schizophrenia, a chronic mental problem, significantly impacts cognition, emotion and social functioning. Conventional pharmacotherapy faces challenges including numerous side effects, low adherence to medication and substantial costs. In this context, group arts therapies (GATs) emerge as a promising complementary approach for symptom alleviation in schizophrenia patients. Nonetheless, the effectiveness and safety of GATs are yet to be firmly established. This study aims to systematically assess the therapeutic impact of all group-based artistic interventions as complementary treatments for schizophrenia, focusing on their potential benefits. Methods and analysis: This study will search four English-language databases (PubMed, Web of Science, Cochrane Library and Embase), two Chinese databases (Wanfang Data and China National Knowledge Infrastructure) and three Korean databases (RISS, Korean Citation Index and DBpia) from their inception until October 2023. It will include all randomised controlled trials that compare GATs for schizophrenia with standard rehabilitation methods. The primary outcome is the improvement in patients’ positive and negative symptoms. Methodologies such as bias risk assessment, data synthesis, sensitivity analysis and subgroup analysis will be implemented using Review Manager V.5.4. Study results with high heterogeneity will be merged using a random-effects model ( I 2 >50% or p<0.1). In cases where meta-analysis is not viable due to significant clinical and methodological heterogeneity, a qualitative summary of the findings will be provided. Ethics and dissemination: The data used in this systematic review are anonymised, devoid of any private information, eliminating the requirement for ethical approval. Dissemination of the research findings will be conducted via peer-reviewed publications. PROSPERO registration number: CRD42023471583.